Search

Search Constraints

You searched for: Author/Creator De Angelis, Mario

Search Results

1. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series. Issue 12 (10th May 2022)

2. MP04-10 RISK OF ORGASMIC FUNCTION IMPAIRMENT AFTER HOLEP – FINDINGS OF A PROSPECTIVE REAL-LIFE TRIAL (EXPHO). (May 2022)

3. MP04-14 PATIENTS ADHERING TO STANDARDIZED PROTOCOLS FOR PFMT AFTER HOLEP SHOW HIGHER RATES OF POSTOPERATIVE INCONTINENCE: REAL-LIFE IMPLICATIONS FOR A RATIONAL MANAGEMENT WORK-UP. (May 2022)

4. MP23-09 ACUTE KIDNEY INJURY AND ITS DURATION IN PATIENTS TREATED WITH RADICAL CYSTECTOMY IN THE ENHANCED RECOVERY AFTER SURGERY ERA: OPTIMIZING THE SELECTION OF PATIENTS FOR RESTRICTIVE FLUID THERAPY. (May 2022)

5. MP48-13 THE KEY ROLE OF CONCOMITANT ANDROGEN-DEPRIVATION THERAPY ON THE EFFICACY OF IMAGING GUIDED TREATMENTS IN MEN WITH BIOCHEMICAL RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND POSITIVE 68GA-PSMA PET/CT SCAN. (May 2022)

6. MP51-08 DOES A POSITIVE MULTI-PARAMETRIC MRI ALWAYS WARRANT PROSTATE BIOPSY? THE IMPORTANCE OF INTEGRATING CLINICAL AND IMAGING DATA BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES. (May 2022)

7. MP51-11 HAS THE INTRODUCTION OF MPMRI IN THE DIAGNOSTIC PATHWAY OF PROSTATE CANCER LED TO IMPROVED ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULT FROM A LARGE SINGLE-INSTITUTIONAL SERIES. (May 2022)

8. MP56-04 THE ROLE OF FDG PET IN THE STAGING OF BLADDER CANCER PATIENTS CANDIDATE FOR RADICAL CYSTECTOMY. (May 2022)

9. PD17-03 COMPARATIVE ANALYSES OF MICRO-ULTRASOUND VERSUS MRI-TARGETED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER. PRELIMINARY RESULTS FROM THE PROSPECTIVE US-MIRROR TRIAL. (May 2022)

10. PD35-02 WHEN IS NEOADJUVANT ANDROGEN DEPRIVATION THERAPY BENEFICIAL FOR HIGHLY AGGRESSIVE PROSTATE CANCER CANDIDATES TO RADICAL PROSTATECTOMY? IMPLICATIONS FOR MULTI-MODAL TAILORED APPROACHES AND TRIALS DESIGN. (1st May 2022)